Intensive Glycemic Control vs Standard Glycemic Control: Number of Participants With > 2 cm of Height Loss
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.195 | 0.182 | 0.208 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.196 | 0.183 | 0.21 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.00145 | -0.0201 | 0.0172 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.993 | 0.902 | 1.09 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.991 | 0.88 | 1.12 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with the outcome on Intensive Glycemic Control than on Standard Glycemic Control | 688 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Intensive Glycemic Control | intensive therapeutic strategy targeting normal glycated hemoglobin (A1C) levels (i.e., below 6.0%)in a population with long-standing type 2 diabetes and a history of cardiovascular disease or significant cardiovascular risk factors | 678 | 3,482 | OG000 | ClinicalTrials.gov |
| Group 2 | Standard Glycemic Control | standard strategy targeting A1C levels from 7.0 to 7.9% in a population with long-standing type 2 diabetes and a history of cardiovascular disease or significant cardiovascular risk factors | 686 | 3,497 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | Number of Participants With > 2 cm of Height Loss | ClinicalTrials.gov |
| Description | Standing height was measured according to a standard protocol at baseline and annual visits on all ACCORD participants. Height loss was compared by treatment assignment using linear mixed models with random intercepts and slopes. Treatment effects were captured by the interaction between treatment assignment and time. The proportions losing \>2 cm of height during follow-up were compared using logistic models. This degree of height loss is associated with incident vertebral fracture with 94% specificity but only 28% sensitivity | ClinicalTrials.gov |
| Time frame | 5 years | ClinicalTrials.gov |
| Population | Among participants in the BONE ancillary study, 6,979 participants had at least one height measurement during follow-up and were included in these analyses. | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Intensive Glycemic Control and Skeletal Health Study | ClinicalTrials.gov |
| NCT number | NCT00324350 | ClinicalTrials.gov |
| Phases | PHASE3 | ClinicalTrials.gov |
| Conditions | Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Coronary Disease | ClinicalTrials.gov |
| Interventions | hypoglycemic agents, hydroxymethylglutaryl-CoA Reductase inhibitors, hypertensive agents | ClinicalTrials.gov |
| Lead sponsor | University of California, San Francisco | ClinicalTrials.gov |
| Results first posted | 2012-10-05 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT00324350?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.